Nasdaq · Healthcare
Stoke Therapeutics, Inc. (STOK)
As-reported financials and recent SEC filings for Stoke Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$184.4M
Net income
$-6.9M
Net margin
-3.7%
Diluted EPS
$-0.12
ROE
-2.0%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $184.4M | $36.6M | $8.8M | $12.4M | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-20.6M | $-101.4M | $-114.8M | $-104.4M | $-86.1M |
| Net income | $-6.9M | $-89.0M | $-104.7M | $-101.1M | $-85.8M |
| Diluted EPS | $-0.12 | $-1.65 | $-2.38 | $-2.60 | $-2.34 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-06
View on EDGAR →1442026-07-01
View on EDGAR →8-K2026-06-30
View on EDGAR →42026-06-18
View on EDGAR →1442026-06-16
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →Largest Healthcare peers
Go deeper on STOK
Search Stoke Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.